Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
$6.34
-$0.25(-2.12%)
At close: 4:00 PM EST
$6.34
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$4.05 - $9.78
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$296.15M
Enterprise Value$297.97M
Total Cash (Recent Filing)$134.81M
Total Debt (Recent Filing)$40.12M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 03, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding46,710,796
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)1.24
Price to Sales (P/S)3.01
P/FCF Ratio-10.58
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.31
Enterprise Value/Gross Profit4.52
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$7.50Price Target Upside18.30% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Alzheimer's Diagnostics Commercial PotentialExecutive's background in commercializing consumer-facing diagnostic tests supports advancement and market-readiness potential for the company's Alzheimer's diagnostics program.
LeadershipBoard appointment of Everett Cunningham as president and chief executive officer brings commercial leadership with a track record in life sciences commercialization that may sharpen strategic priorities and execution.
Merger Synergies And IntegrationCommitment to implement $85 million in annual merger synergies and positive early commentary on Akoya integration point to potential cost savings and customer revenue cross-sell opportunities.
Bears Say
Acquisition ControversyInvestor opposition to the spatial biology acquisition signals governance and strategic risk that may undermine investor confidence.
Core Consumables DemandDeclines in core consumables revenue amid an unfavorable macro environment indicate persistent demand weakness in key end markets.
Funding And Biopharma HeadwindsContinued NIH funding uncertainty and headwinds in the biopharma sector may keep pressure on sales and slow recovery in revenue growth.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.05 and its highest was $9.78 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $296.15M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Mar 03, 2026 which is in 29 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Nov 10, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.272.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.45.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 46,710,796 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.50 (18.30% Upside)
$7.50 (18.30% Upside)
Hedge Fund Trend
Decreased
By 234.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-29.28%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
QTRX Company Deck
QTRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong execution in revenue growth and successful integration of Akoya, contributing to a positive cash position and early momentum in diagnostics. However, challenges remain due to declines in core Simoa revenue and weaknesses in U.S. academic and pharmaceutical markets, compounded by the ongoing government shutdown. Despite these challenges, the company is positioned well for future growth with early commercial and cross-selling momentum.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$7.50
▲(18.30% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.25% Insiders
16.17% Mutual Funds
1.38% Other Institutional Investors
64.74% Public Companies and
Individual Investors